The Ghana Health Service (GHS) has said it has put in place adequate measures to contain the outbreak of the Marburg virus disease in Ghana.
According to the GHS, more than 90 contacts, including health workers and community members, have been identified and are being monitored following the suspected case in the country.
Speaking with Benjamin Offei-Addo on the Asaase Breakfast Show on Tuesday ( 19 July), the director general of GHS, Dr Patrick Kumah-Aboagye said none of those quarantined so far has contracted the disease.
“We have trained teams in communities and response teams that are ready and will be on hand when needed to ensure that even if the virus crops up … we can quickly ensure it does not spread.”
“We have surveillance reporting on any suspected recordings and cases of people who exhibit symptoms [of the Marburg virus]. And this is why we were able to contain it so quickly,” Dr Kumah-Aboagye said.
He added, “So far, we have done contact tracing of those who came into contact with the people who had contracted the virus … And we have confirmed that none have contracted it.”
The World Health Organization’s (WHO) collaborating centre laboratory has confirmed earlier results of Ghana’s first outbreak of Marburg virus disease.
The Institut Pasteur in Dakar, Senegal received samples from each of the two patients from the southern Ashanti region of Ghana – both deceased and unrelated – who showed symptoms including diarrhoea, fever, nausea and vomiting, the WHO said.
“The laboratory corroborated the results from the Noguchi Memorial Institute for Medical Research, which suggested their illness was due to the Marburg virus. One case was a 26-year-old male who checked into a hospital on 26 June 2022 and died on 27 June. The second case was a 51 -year-old male who reported to the hospital on 28 June and died on the same day. Both cases sought treatment at the same hospital within days of each other.”
WHO has been supporting a joint national investigative team in the Ashanti Region as well as Ghana’s health authorities by deploying experts, making available personal protective equipment, bolstering disease surveillance, testing, tracing contacts and working with communities to alert and educate them about the risks and dangers of the disease, and to collaborate with the emergency response teams. In addition, a team of WHO experts will be deployed over the next couple of days to provide coordination, risk assessment and infection prevention measures.
“Health authorities have responded swiftly, getting a head start preparing for a possible outbreak. This is good because without immediate and decisive action, Marburg can easily get out of hand. WHO is on the ground supporting health authorities and now that the outbreak is declared, we are marshalling more resources for the response,” said Dr Matshidiso Moeti, WHO Regional Director for Africa.
Marburg is a highly infectious viral haemorrhagic fever in the same family as the more well-known Ebola virus disease. It is only the second time the zoonotic disease has been detected in West Africa. Guinea confirmed a single case in an outbreak that was declared over on 16 September 2021, five weeks after the initial case was detected.
Previous outbreaks and sporadic cases of Marburg in Africa have been reported in Angola, the Democratic Republic of the Congo, Kenya, South Africa and Uganda. WHO has reached out to neighbouring high-risk countries and they are on alert.
Marburg is transmitted to people from fruit bats and spreads among humans through direct contact with the bodily fluids of infected people, surfaces and materials. Illness begins abruptly, with high fever, severe headache and malaise. Many patients develop severe haemorrhagic signs within seven days. Case fatality rates have varied from 24% to 88% in past outbreaks depending on virus strain and the quality of case management. Although there are no vaccines or antiviral treatments approved to treat the virus, supportive care – rehydration with oral or intravenous fluids – and treatment of specific symptoms, improves survival. A range of potential treatments, including blood products, immune therapies and drug therapies, as well as candidate vaccines with phase 1 data are being evaluated.